The WHO said that the effort to establish the stockpile was led by the International Coordinating Group on Vaccine Provision, which includes the WHO, UNICEF, the IFRC, and MSF, with financial support from Gavi, the Vaccine Alliance.

“The stockpile will allow countries, with the support of humanitarian organisations, to contain future Ebola epidemics by ensuring timely access to vaccines for populations at risk during outbreaks,” WHO states.

The injectable single-dose Ebola vaccine (rVSV∆G-ZEBOV-GP, live) is manufactured by Merck, Sharp and Dohme (MSD) Corp.; and developed with financial support from the government of the United States of America.

The European Medicines Agency licensed the Ebola vaccine in November 2019, and the vaccine is now prequalified by WHO, and licensed by the US Food and Drug Administration as well as in eight African countries.

Before achieving licensure, the vaccine was administered to more than 350,000 people in Guinea and in the 2018-2020 Ebola outbreaks in the Democratic Republic of the Congo under a protocol for “compassionate use.”

The vaccine, which is recommended by the Strategic Advisory Group of Experts, SAGE, on Immunisation for use in Ebola outbreaks as part of a broader set of Ebola outbreak response tools, protects against the Zaire ebolavirus species which is most commonly known to cause outbreaks.

Speaking on the occasion, WHO Director-General, Dr. Tedros Adhanom Ghebreyesus, stated, “The COVID-19 pandemic is reminding us of the incredible power of vaccines to save lives from deadly viruses.

“Ebola vaccines have made one of the most feared diseases on earth preventable. This new stockpile is an excellent example of solidarity, science and cooperation between international organisations and the private sector to save lives.”

UNICEF manages the stockpile on behalf of the international coordinating group which, as with stockpiles of cholera, meningitis and yellow fever vaccines, will be the decision-making body for its allocation and release.

The stockpile is stored in Switzerland and ready to be shipped to countries for emergency response.

“The decision to allocate the vaccine will be made within 48 hours of receiving a request from a country; vaccines will be made available together with ultra-cold chain packaging by the manufacturer for shipment to countries within 48 hours of the decision.

“The targeted overall delivery time from the stockpile to countries is seven days,” the announcement stated.

Responding, UNICEF Executive Director, Henrietta Fore, said, “We are proud to be part of this unprecedented effort to help bring potential Ebola outbreaks quickly under control.

“We know that when it comes to disease outbreaks, preparedness is key. This Ebola vaccine stockpile is a remarkable achievement — one that will allow us to deliver vaccines to those who need them the most as quickly as possible.”

The WHO notes that, because Ebola outbreaks are relatively rare and unpredictable, there is no natural market for the vaccine.

Vaccines are only secured through the establishment of the stockpile and are available in limited quantities, the agency warns, adding, “The Ebola vaccine is reserved for outbreak response to protect people at the highest risk of contracting Ebola – including healthcare and frontline workers.”

“This is an important milestone. Over the past decade alone we have seen Ebola devastate communities in West and Central Africa, always hitting the poorest and most vulnerable the hardest,” said IFRC Secretary General, Jagan Chapagain. “Through each outbreak, our volunteers have risked their lives to save lives. With this stockpile, it is my hope that the impact of this terrible disease will be dramatically reduced.”

“The creation of an Ebola vaccine stockpile under the ICG is a positive step”, said Dr Natalie Roberts, Programme Manager, MSF Foundation. “Vaccination is one of the most effective measures to respond to outbreaks of vaccine preventable diseases, and Ebola is no exception.

“An Ebola vaccine stockpile can increase transparency in the management of existing global stocks and the timely deployment of the vaccine where it’s most needed, something MSF has called for during recent outbreaks in the Democratic Republic of Congo.”

Depending on the rate of vaccine deployment, it could take two to three years to reach the SAGE-recommended level of 500,000 doses for the emergency stockpile of Ebola vaccines, WHO said, adding that the international bodies and vaccine manufacturers are continuously assessing options to increase vaccine supply should global demand increase.

source: Punch